ACTO offers an AI-first IFE platform focused on closing gaps in HCP omnichannel engagement for life sciences commercial teams. Its product roadmap centers on the LAICA suite, announced in 2022, and integrated Generative AI capabilities. Planned GenAI features include field rep real-time knowledge assistance, simulated rep–manager roleplay and coaching, commercial learning content creation assistance, and commercial leader field insight assistance. The company announced a dedicated US$10M investment into GenAI to accelerate those capabilities. Funding for this effort comes from ACTO’s venture capital backers alongside public and cloud partners, and the company is piloting real-world use cases with customers via the AWS Jumpstart Program. Executives and investors frame ACTO as an early AI-focused category leader on the commercial side of life sciences, citing work that began as early as 2019. ACTO provides an AI-powered omnichannel learning and enablement SaaS platform that helps global life‑sciences companies educate and engage field teams and learners across the care continuum. Commercial and clinical leaders use ACTO to deliver unified educational experiences and sales enablement at scale. The company maintains a network of partnerships with content agencies, data providers, and technology companies to build an ecosystem for life sciences. ACTO recently introduced a conversational assistant, LAICA™, as part of its product roadmap to make commercial learning easier and more engaging. The company is experiencing robust user and revenue growth, reporting a 500% increase in annual recurring revenue since 2018 and total invested capital exceeding US$30 million. Proceeds from its latest financing will be used to accelerate growth, expand capabilities, and pursue business and partnership opportunities. ACTO builds an AI-powered mobile platform that educates and supports stakeholders in life sciences, enabling training, content delivery, and sales enablement. The platform offers self-paced modules called ActionPacks containing multimedia, quizzes, 3D content, authoring tools, and event engagement features. ACTO has launched conversational AI capabilities that surface information about drugs and medical devices to support doctors, nurses, and other providers. Managers can certify reps with digital signatures and PDF certificates, run assessments, and deliver AI-personalized notifications and reference guides. The platform includes deep search, multi-channel integrations, permissioning, tracked mail/text links, and CRM integrations that generate reports by individual, team, and territory. ACTO says tens of thousands of reps rely on it across 50 life sciences companies, including AstraZeneca, Teleflex, and Philips Respironics. The company closed an $11.5 million funding round to bolster these capabilities and accelerate digital engagement.

Total raised

$40M

Funding rounds

3

Latest round

Equity

Latest activity

Sep 2024